Abstract
More than 3 million Australians are estimated to have migraine disorders, and over a quarter of a million Australians are estimated to have medication overuse headache (MOH). The personal, societal and economic burden of MOH is high. MOH impacts an individual’s ability to work or study, care for family or themselves, culminating in poor quality of life. Accurate and timely diagnosis and treatment of MOH are imperative. Withdrawal failures and relapse rates are high in MOH.Treatment of MOH is aimed at ceasing medication overuse and reducing monthly migraine days with the aim of achieving a pattern of well-controlled episodic migraine. Current treatment approaches in routine practice include withdrawal with preventive treatment, withdrawal with optional preventive treatment in the subsequent weeks and preventive treatment without withdrawal. This viewpoint article provides an overview of managing MOH in Australian clinical practice, with a focus on the importance of patient education and the role of preventive treatment in supporting patients as they withdraw from acute migraine medication(s).
Subject
Neurology (clinical),Neurology
Reference29 articles.
1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
2. Fischer MA , Headache A . Medication-overuse headache. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. Available: https://www.ncbi.nlm.nih.gov/books/NBK538150/
3. Vandenbussche N , Laterza D , Lisicki M , et al . Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 2018;19:50. doi:10.1186/s10194-018-0875-x
4. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019;Safiri;Pain,2022
5. Australian Bureau Statistics . National, state and territory population. 2019. Available: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2019